Skip to main content

In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.

Publication ,  Journal Article
Kelsey, MD; Newby, LK
Published in: Ann Intern Med
March 2022

Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

March 2022

Volume

175

Issue

3

Start / End Page

JC26

Location

United States

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Humans
  • Glucagon-Like Peptide 1
  • General & Internal Medicine
  • Dipeptidyl-Peptidase IV Inhibitors
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kelsey, M. D., & Newby, L. K. (2022). In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. Ann Intern Med, 175(3), JC26. https://doi.org/10.7326/J22-0003
Kelsey, Michelle D., and L Kristin Newby. “In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.Ann Intern Med 175, no. 3 (March 2022): JC26. https://doi.org/10.7326/J22-0003.
Kelsey MD, Newby LK. In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. Ann Intern Med. 2022 Mar;175(3):JC26.
Kelsey, Michelle D., and L. Kristin Newby. “In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.Ann Intern Med, vol. 175, no. 3, Mar. 2022, p. JC26. Pubmed, doi:10.7326/J22-0003.
Kelsey MD, Newby LK. In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. Ann Intern Med. 2022 Mar;175(3):JC26.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

March 2022

Volume

175

Issue

3

Start / End Page

JC26

Location

United States

Related Subject Headings

  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Humans
  • Glucagon-Like Peptide 1
  • General & Internal Medicine
  • Dipeptidyl-Peptidase IV Inhibitors
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences